Get a fresh start.
Add this topic to your myFT Digest for news straight to your inbox
Move could raise pressure to step up disposals or splitting of chemicals and pharma units
German group seeks to regain investor confidence following legal setbacks
New cancer drug promises to become a blockbuster but there are big hurdles to overcome
The company said full-year sales would be in line with guidance
Judge reduces punitive damages company has to pay to cancer patient
A balance sheet that ‘does not quite balance’ makes Aston Martin a sell, says Jefferies
Fears that the $63bn deal will destroy value are making investors jittery
German group had counted on a stronger contribution from US rival to lift results
The public-private NHS, Russian anti-vaxx bots, the burden of booze
US court ruled earlier this month that Roundup and Ranger Pro products cause cancer
Vocal investors increasingly behind corporate shake-ups on the continent
California court declines to hear Monsanto appeal over chemical in Roundup weedkiller
Legal battle underlines fears that Monsanto was a bad buy
US groundskeeper awarded $289m in damages after using Monsanto weedkiller
Investment bank makes money from both advice and financing for Murdoch business
Bayer benefits as investors buy into deals from weaker investment grade borrowers
Long-running takeover of controversial group set to complete this week
Move brings closer creation of world’s largest maker of seeds and pesticides
US regulators demand $9bn in divestments to approve deal
